L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin
- PMID: 22110268
- PMCID: PMC3218156
- DOI: 10.3748/wjg.v17.i39.4414
L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin
Abstract
Aim: To evaluate the efficacy of L-carnitine on alleviating anemia, thrombocytopenia and leukopenia, and minimizing dose reductions in patients with chronic hepatitis C virus (HCV) in treatment with Interferon α (IFN-α) plus ribavirin.
Methods: Sixty-nine patients with chronic hepatitis C were enrolled in the study and divided into two groups. group A (n = 35) received Peg-IFN-α 2b plus ribavirin plus L-carnitine, and group B (n = 34) received Peg-IFN-α and ribavirin for 12 mo. All patients underwent laboratory investigations including: red cell count, hemoglobin, white cell count, platelets, bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and viremia.
Results: After 12 mo in group A compared to group B we observed significant differences in AST 108.8 vs 76.8 (IU/L; P < 0.001), ALT 137.9 vs 112.3 (IU/L; P < 0.001), viremia 4.04 vs 2.36 (× 10(6) copies/mL; P < 0.001), Hb 1 vs 3.5 (g/dL; P < 0.05), red blood cells 0.3 vs 1.1 (× 10(12)/L; P < 0.001), white blood cells 1.5 vs 3 (× 10(9)/L; P < 0.001) and platelets 86 vs 85 (× 10(9)/L; P < 0.001). The end treatment responders were 18 vs 12 (60% vs 44%) and the non responders were 12 vs 15 (40% vs 50%) [odds ratio (OR) 1.65, 95% CI = 0.65-5.37, P < 0.05]. In group A compared to group B there was a significant improvement of sustained virological response in 15 vs 7 patients (50% vs 25%), while the relapsers were 3 vs 5 (10% vs 18%) (OR 3.57, 95% CI = 0.65-19.3, P < 0.001).
Conclusion: L-carnitine supplementations modulate erythropoiesis, leucopoiesis and thrombocytopoiesis, and may be useful in patients treated for HCV. L-carnitine treatment offers the possibility of achieving a sustained virological response while preventing overtreatment.
Keywords: Anemia; Chronic hepatitis C; Interferon; L-carnitine.
Figures
Similar articles
-
Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.Int Urol Nephrol. 2011 Sep;43(3):865-73. doi: 10.1007/s11255-010-9756-1. Epub 2010 May 19. Int Urol Nephrol. 2011. PMID: 20490669
-
Treatment with peginterferon plus ribavirin vs. interferon plus ribavirin for 48 weeks in Chinese patients with chronic hepatitis C.Int J Clin Pract. 2009 Sep;63(9):1334-9. doi: 10.1111/j.1742-1241.2009.02082.x. Int J Clin Pract. 2009. PMID: 19691617 Review.
-
Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.J Gastroenterol Hepatol. 2008 Jun;23(6):861-6. doi: 10.1111/j.1440-1746.2008.05397.x. Epub 2008 Apr 19. J Gastroenterol Hepatol. 2008. PMID: 18422960 Clinical Trial.
-
Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.New Microbiol. 2005 Jan;28(1):13-21. New Microbiol. 2005. PMID: 15782622 Clinical Trial.
-
Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. doi: 10.3310/hta8390. Health Technol Assess. 2004. PMID: 15461877 Review.
Cited by
-
Carnitine derivatives beyond fatigue: an update.Curr Opin Gastroenterol. 2023 Mar 1;39(2):125-128. doi: 10.1097/MOG.0000000000000906. Epub 2023 Jan 5. Curr Opin Gastroenterol. 2023. PMID: 36821461 Free PMC article. Review.
-
Impact of l-Carnitine Supplementation on Liver Enzyme Normalization in Patients with Chronic Liver Disease: A Meta-Analysis of Randomized Trials.J Pers Med. 2022 Jun 27;12(7):1053. doi: 10.3390/jpm12071053. J Pers Med. 2022. PMID: 35887550 Free PMC article. Review.
-
Carnitine Serum Levels in Frail Older Subjects.Nutrients. 2020 Dec 19;12(12):3887. doi: 10.3390/nu12123887. Nutrients. 2020. PMID: 33352627 Free PMC article.
-
The Nutraceutical Value of Carnitine and Its Use in Dietary Supplements.Molecules. 2020 May 1;25(9):2127. doi: 10.3390/molecules25092127. Molecules. 2020. PMID: 32370025 Free PMC article. Review.
-
Effects of carnitine supplementation on liver aminotransferase enzymes: A systematic review and meta-analysis of randomized controlled clinical trials.Indian J Gastroenterol. 2019 Dec;38(6):470-479. doi: 10.1007/s12664-019-00983-2. Epub 2019 Dec 11. Indian J Gastroenterol. 2019. PMID: 31828538
References
-
- Malaguarnera M, Restuccia S, Trovato G, Siciliano R, Motta M, Trovato B. Interferon-a Treatment in Patients with Chronic Hepatitis C: A Meta-Analytic Evaluation. Clinical Drug Investigation. 1995;9:141–149.
-
- Malaguarnera M, Di Fazio I, Restuccia S, Pistone G, Restuccia N, Trovato BA. Efficacy of different schedules in the management of chronic hepatitis C with interferon-alpha. Ann Med. 1998;30:213–217. - PubMed
-
- Malaguarnera M, Di Fazio I, Restuccia S, Pistone G, Ferlito L, Rampello L. Interferon alpha-induced depression in chronic hepatitis C patients: comparison between different types of interferon alpha. Neuropsychobiology. 1998;37:93–97. - PubMed
-
- Malaguarnera M, Laurino A, Di Fazio I, Pistone G, Castorina M, Guccione N, Rampello L. Neuropsychiatric effects and type of IFN-alpha in chronic hepatitis C. J Interferon Cytokine Res. 2001;21:273–278. - PubMed
-
- Malik UR, Makower DF, Wadler S. Interferon-mediated fatigue. Cancer. 2001;92:1664–1668. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical